Invivoscribe, Inc.

Invivoscribe is a San Diego-based molecular diagnostics company founded in 1995, specializing in precision oncology testing and personalized molecular medicine for hematologic malignancies. The company develops and manufactures CE-marked in vitro diagnostic assays, research-use-only (RUO) assays, analyte-specific reagents (ASRs), and DNA/RNA controls under ISO 13485 design control. Core product lines include next-generation sequencing (NGS) panels for clonality testing (B- and T-cell), minimal residual disease (MRD) assays (LymphTrack®, LeukoStrat® FLT3-ITD and NPM1), and companion diagnostics (CDx) for precision oncology drug therapies. Invivoscribe operates LabPMM®, a CAP-accredited clinical laboratory with multiparametric flow cytometry and molecular testing services, serving clinical laboratories, pharmaceutical companies, and researchers across 160+ countries and 700+ laboratories worldwide. The company also provides bioinformatics software, custom assay development, and turn-key CDx collaboration for pharmaceutical partners, emphasizing regulatory expertise and streamlined drug approval pathways.